Concert Pharmaceuticals’ (CNCE) “Hold” Rating Reiterated at Mizuho

Concert Pharmaceuticals (NASDAQ:CNCE)‘s stock had its “hold” rating restated by Mizuho in a note issued to investors on Tuesday, February 13th. They presently have a $23.00 price objective on the biotechnology company’s stock. Mizuho’s price objective suggests a potential upside of 8.90% from the stock’s previous close.

Other research analysts have also issued reports about the stock. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday, November 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $30.00 price objective on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $24.33.

Concert Pharmaceuticals (NASDAQ:CNCE) traded down $0.36 during mid-day trading on Tuesday, hitting $21.12. 151,000 shares of the company were exchanged, compared to its average volume of 483,385. Concert Pharmaceuticals has a 1 year low of $9.04 and a 1 year high of $30.71. The stock has a market capitalization of $489.15, a price-to-earnings ratio of 5.68 and a beta of 1.23.

In other news, Director Richard Aldrich sold 31,236 shares of Concert Pharmaceuticals stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $19.14, for a total transaction of $597,857.04. Following the completion of the sale, the director now directly owns 286,975 shares in the company, valued at $5,492,701.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of Concert Pharmaceuticals stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total value of $34,188,112.40. The disclosure for this sale can be found here. Insiders have sold 1,433,248 shares of company stock valued at $37,226,329 over the last ninety days. 10.10% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY acquired a new position in shares of Concert Pharmaceuticals during the 4th quarter worth approximately $164,000. MetLife Investment Advisors LLC purchased a new position in shares of Concert Pharmaceuticals in the 4th quarter valued at approximately $232,000. SG Americas Securities LLC purchased a new position in shares of Concert Pharmaceuticals in the 3rd quarter valued at approximately $153,000. Alliancebernstein L.P. purchased a new position in shares of Concert Pharmaceuticals in the 2nd quarter valued at approximately $174,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in shares of Concert Pharmaceuticals in the 4th quarter valued at approximately $329,000. Institutional investors and hedge funds own 76.61% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Concert Pharmaceuticals’ (CNCE) “Hold” Rating Reiterated at Mizuho” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/02/21/concert-pharmaceuticals-cnce-receives-hold-rating-from-mizuho.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply